BCN HEALTH publishes a study evaluating the incidence and medical cost associated to intrahepatic cholangiocarcinoma in Spain
The company conducted a retrospective study based on the records of patients hospitalized due to intrahepatic cholangiocarcinoma (iCCA) and treated in Spanish public and private hospitals between January of 2000 and December of 2018
BCN HEALTH has published the study ‘Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018)’ in the journal ‘Expert Review of Pharmacoeconomics & Outcomes Research, an international journal publishing rigorously peer-reviewed articles on several aspects of pharmacoeconomics.
BCN HEALTH conducted a retrospective study based on the records of patients hospitalized due to intrahepatic cholangiocarcinoma (iCCA) and treated in Spanish public and private hospitals between January of 2000 and December of 2018. The objective of this study was to evaluate incidence and mortality of the disease at the hospital level and to calculate the associated medical costs.
The files obtained corresponded to 23,315 patients diagnosed with iCCA; 56% of the patients were males, with a median age of 73 years. Hospital incidence was 7 per 10,000 persons in 2018, increasing significantly over the study period. In-hospital mortality was 32% the year 2018 and remained stable over the study period.
Overall, 28% of all registered admissions were associated to metastatic events, and median length of hospital stay was 10 days. The mean annual direct medical cost of secondary care was €9417 per patient the year 2017, increasing significantly between 2000 and 2008 and stabilizing after 2009.
More information can be found at https://doi.org/10.1080/14737167.2021.1842201.